Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...
Mesoblast (MESO) announced that it has entered into the Medicaid National Drug Rebate Agreement, NDRA, with the U.S. Centers for Medicare & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback